Join
Live feed
·
INSIDERFilingvia Quantisnow
Alnylam Pharmaceuticals Inc. logo

CSO & EVP, Head of Research Fitzgerald Kevin Joseph was granted 2,851 shares and sold $632,759 worth of shares (1,396 units at $453.27), increasing direct ownership by 7% to 22,719 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ALNY (Alnylam Pharmaceuticals Inc.) and more on Quantisnow.